The largest series of bortezomib–dexamethasone use in POEMS recently reported on 69 patients at 1.3 mg/m2 subcutaneously [8] with excellent outcomes (haematological complete remission rate 46%, VEGF complete remission rate 71%, neurological improvement 88%, 2‐year time to next treatment 66%) and only 3% developed grade 1 bortezomib‐induced neuropathy after six cycles of treatment, which was reversible after drug withdrawal. Here, VEGFA is linked to neuropathy.